Literature DB >> 19036622

The activity of wild type and mutant phenylalanine hydroxylase with respect to the C-oxidation of phenylalanine and the S-oxidation of S-carboxymethyl-L-cysteine.

Glyn B Steventon1, Stephen C Mitchell, Belen Pérez, Lourdes R Desviat, Magdalena Ugarte.   

Abstract

The involvement of the enzyme, phenylalanine hydroxylase (PAH), in the S-oxidation of S-carboxymethyl-L-cysteine (SCMC) is now firmly established in man and rat. However, the underlying role of the molecular genetics of PAH in dictating and influencing the S-oxidation polymorphism of SCMC metabolism is as yet unknown. In this work we report that the S-oxidation of SCMC was dramatically reduced in the tetrahydrobiopterin (BH(4)) responsive mutant PAH proteins (I65T, R68S, R261Q, V388M and Y414C) with these enzymes possessing between 1.2% and 2.0% of the wild type PAH activity when SCMC was used as substrate. These same mutant proteins express between 23% and 76% of the wild type PAH activity when phenylalanine was used as the substrate. The PAH mutant proteins (R158Q, I174T and R408W) that result in the classical phenylketonuria (PKU) phenotype expressing 0.2-1.8% of the wild type PAH activity when using phenylalanine as substrate were found to have <0.1% of the wild type PAH activity when SCMC was used as the substrate. Mutations that result in PAH proteins retaining some residual PAH activity with phenylalanine as substrate have <2.0% residual activity when SCMC was used as a substrate. This investigation has led to the hypothesis that the S-oxidation polymorphism in man is a consequence of an individual carrying one mutant PAH allele which has resulted in the loss of the ability of the residual PAH protein to undertake the S-oxidation of SCMC in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036622     DOI: 10.1016/j.ymgme.2008.10.011

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  1 in total

1.  Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels.

Authors:  Dona M Kanavy; Shannon M McNulty; Meera K Jairath; Sarah E Brnich; Chris Bizon; Bradford C Powell; Jonathan S Berg
Journal:  Genome Med       Date:  2019-11-29       Impact factor: 11.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.